单倍体相合造血干细胞移植治疗重型再生障碍性贫血进展  

Advances in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia

作　　者：王丽[1] 吴亚妹[1] 曹永彬[1] 李晓红[1] 徐丽昕[1] 汪海涛[1] 高亚会 吴晓雄[1] 

机构地区：[1]解放军总医院第一附属医院血液科,北京100048

出　　处：《解放军医学院学报》2017年第3期274-276,共3页Academic Journal of Chinese PLA Medical School

基　　金：部委级资助项目;全军医学科技青年培育项目(16QNO138)~~

摘　　要：同胞及无关供者全相合造血干细胞移植是治疗重型再生障碍性贫血(severe aplastic anemia,SAA)的一线治疗方案,但该治疗供者匮乏,免疫抑制剂治疗部分无效、复发率高。单倍体相合造血干细胞移植近年发展迅速,疗效已接近全相合移植。单倍体相合造血干细胞移植扩大了移植供源,抓住了最佳治疗时机,使广大患者获益。本文综合目前国内外相关研究进展及临床治疗经验,对单倍体相合造血干细胞移植治疗SAA的研究进展进行综述。Matched sibling donor （MSD） or matched unrelated donor （MUD） hematopoietic stem cell transplantation is the front- line therapy for severe aplastic anemia. When MSD or MUD is not available, then intensive immunosuppressive therapy （IST） is indicated. However, IST has a high relapse rate due to lack of response. Haploidentical hematopoietic stem cell transplantation （Haplo-HSCT） has been developing so rapidly that they could now replace the transplantation from identical siblings with similar efficacy. The application of Haplo-HSCT terminate the era of donor shortage and bring benefit to the patients. This review will focus on the progress of the therapeutic effect of Haplo-HSCT in the treatment of SAA.

关 键 词：重型再生障碍性贫血 造血干细胞移植 单倍体 

分 类 号：R556.5[医药卫生—血液循环系统疾病]